Antigen News and Research

RSS

Study shows immune therapy can prevent pregnancy in mammals including humans

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males.

1 Apr 2011

Immune therapy can control fertility in mammals

31 Mar 2011

Roche launces new GS GType HLA Primer Sets for HLA genotyping

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci of the Human Leukocyte Antigen (HLA) genes.

30 Mar 2011

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have employed a strategy using a mouse model to target important mechanisms inside the most challenging breast cancer cells. Earlier studies at Cedars-Sinai found a similar approach effective in attacking malignant brain tumor targets.

30 Mar 2011

New study: Many elderly men may overuse PSA testing

A new study on the use of prostate-specific antigen-based prostate cancer screening in the United States found that many elderly men may be undergoing unnecessary prostate cancer screenings.

29 Mar 2011

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

The U.S. Food and Drug Administration today approved Yervoy to treat patients with late-stage melanoma, the most dangerous type of skin cancer.

28 Mar 2011

FDA approves ipilimumab for metastatic melanoma treatment

The U.S. Food and Drug Administration announced today its approval of a new treatment for advanced melanoma, the deadliest and most difficult-to-treat form of skin cancer.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

FDA approves ipilimumab to treat metastatic melanoma

The US Food and Drug Administration announced today that the drug ipilimumab has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

28 Mar 2011

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort Lauderdale, Florida.

25 Mar 2011

Robotic surgery for prostate cancer safe over the long term

In the first study of its kind, urologists and biostatisticians at Henry Ford Hospital have found that robot-assisted surgery to remove cancerous prostate glands is safe over the long term, with a major complication rate of less than one percent.

24 Mar 2011

John Muir Health provides new cancer treatment using Varian's RapidArc radiation therapy

John Muir Health is offering a new cancer treatment option using the latest technology from Varian Medical Systems - The Trilogy Linear Accelerator with RapidArc Technology. The new accelerator, located at John Muir Medical Center, Concord, significantly shortens treatment sessions from 15-20 minutes to 2-5 minutes, while improving the precision of the radiotherapy.

24 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Life Technologies enters clinical trials for DNA SBT platform for analysis of Human Leukocyte Antigen system

Life Technologies Corporation today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human Leukocyte Antigen (HLA) system. Submission for 510(k) clearance of this SBT platform will follow completion of the clinical trials, which is anticipated this summer.

21 Mar 2011

Researchers identify protein that triggers immune response in TB-infected people

Scientists have discovered a protein secreted by tuberculosis bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be used to improve diagnosis of TB.

19 Mar 2011

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

18 Mar 2011

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

Although it has been known for some time that vitamin A deficiency is linked with an impaired ability to resist infections, exactly how vitamin A and its metabolites contribute to the immune response is not well understood.

18 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

17 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011